TAT-11: NorthStar Program for Production of Ac-225

Ottawa, ON, Canada (UroToday.com) Northstar has completed a “proof of concept” for production of Ac225 from proton irradiation of Thorium targets. The initial experiment used 8 GeV protons from the Fermilab Booster accelerator.

This would not be available for commercial production (and the proton energy is too high for optimal production), so the company is seeking partners to provide a proton source. They hope to scale up to a production rate of 10-100 mCi of Ac225 by the end of 2020.

Presented by: James Harvey, PhD, NorthStar Medical Technologies, LLC, Madison, Wisconsin, United States

Written by: William Carithers, Lawrence Berkeley National Laboratory at the 11th International Symposium on Targeted Alpha Therapy (TAT-10) April 1 - April 4, 2019 - Ottawa, ON, Canada

Login